Tumor targeting using canine parvovirus nanoparticles

Current Topics in Microbiology and Immunology

Volumn 327, Issue , 2009, Pages 123-141

  Singh, P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; DYE; NANOMATERIAL; NANOPARTICLE; PROTEIN; TRANSFERRIN RECEPTOR;

BINDING AFFINITY; BIOMEDICINE; CANCER CONTROL; CELL CYCLE; CHEMICAL MODIFICATION; DERIVATIZATION; FELINE PANLEUKOPENIA VIRUS; HUMAN; INTERNALIZATION; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULAR LIBRARY; MOLECULAR RECOGNITION; NANOBIOTECHNOLOGY; NANODEVICE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; REVIEW; SURFACE PROPERTY; TUMOR CELL; VIRUS CAPSID; VIRUS ISOLATION; VIRUS LIKE AGENT; VIRUS PARTICLE;

ANIMALS; DOGS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; PARVOVIRUS, CANINE; VIRION;

CANINE PARVOVIRUS; MIRIDAE;

EID: 58349086145     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-69379-6_6     Document Type: Review

References (86)

1. American Cancer Society (2006) Cancer facts and figures, 2006. www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf. American Cancer Society, Atlanta, GA. Cited 14 April 2008
2. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102-111
3. Bashir T, Rommelaere J, Cziepluch C (2001) In vivo accumulation of cyclin A and cellular replication factors in autonomous parvovirus minute virus of mice-associated replication bodies. J Virol 75:4394-4398
4. Becker A, Riefke B, Ebert B, et al (2000) Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 72:234-241
5. Ben-Gary H, McKinney RL, Rosengart T, et al (2002) Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther 6:287-297
6. Bloom ME, Young NS (2001) Parvoviruses. In: Knipe DM Howley PM (eds) Fields virology, 4th edn., vol. 2. Lippincott Williams and Wilkins, Philadelphia, pp 2361-2379
7. Brandenburger A, Legendre D, Avalosse B, Rommelaere J (1990) NS-1 and NS-2 proteins may act synergistically in the cytopathogenicity of parvovirus MVMp. Virology 174:576-584
8. Bridges KR, Smith BR (1985) Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. J Clin Invest 76:913-918
9. Brown KE, Anderson SM, Young NS (1993) Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262:114-117
10. Brown WL, Mastico RA, Wu M, et al (2002) RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45:371-380
11. Brumfield S, Willits D, Tang L, et al (2004) Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J Gen Virol 85:1049-1053
12. Caillet-Fauquet P, Perros M, Brandenburger A, et al (1990) Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 9:2989-2995
13. Chatterji A, Ochoa W, Shamieh L, et al (2004) Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 15:807-813
14. Christ M, Louis B, Stoeckel F, et al (2000) Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum Gene Ther 11:415-427
15. Cotmore SF, Tattersall P (1987) The autonomously replicating parvoviruses of vertebrates. Adv Virus Res 33:91-174
16. Deleu L, Pujol A, Faisst S, Rommelaere J (1999) Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J Virol 73:3877-3885
17. Doronina SO, Toki BE, Torgov MY, et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
18. Douglas T, Young M (2006) Viruses: making friends with old foes. Science 312:873-875
19. Edwards BK, Brown ML, Wingo PA, et al (2005) Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427
20. Eichwald V, Daeffler L, Klein M,, et al (2002) The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J Virol 76:10307-10319
21. Engler H, Machemer T, Philopena J, et al (2004) Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328:52-61
22. Geletneky K, Herrero YCM, Rommelaere J, Schlehofer JR (2005) Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health 52:327-330
23. Gomme PT, McCann KB, Bertolini J (2005) Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 10:267-273
24. Goren D, Horowitz AT, Tzemach D, et al (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949-1957
25. Green NK, Herbert CW, Hale SJ, et al (2004) Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 11:1256-1263
26. Gupta SS, Kuzelka J, Singh P, et al (2005) Accelerated bioorthogonal conjugation: a practical method for ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconj Chem 16:1572-1579
27. Hashizume H, Baluk P, Morikawa S, et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380
28. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ (2002) The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 13:129-141
29. Hogemann-Savellano D, Bos E, Blondet C, et al (2003) The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5:495-506
30. Hueffer K, Parrish CR (2003) Parvovirus host range, cell tropism and evolution. Curr Opin Microbiol 6:392-398
31. Inoue T, Cavanaugh PG, Steck PA, et al (1993) Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 156:212-217
32. LeCesne A, Dupressoir T, Janin N, et al (1993) Intra-lesional administration of a live virus, parvovirus H-1(PVH-1) in cancer patients: a feasibility study. Proc Ann Meet Am Soc Clin Oncol 12:297
33. Lee GK, Maheshri N, Kaspar B, Schaffer DV (2005) PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng 92:24-34
34. Legrand C, Rommelaere J, Caillet-Fauquet P (1993) MVM(p) NS-2 protein expression is required with NS-1 for maximal cytotoxicity in human transformed cells. Virology 195:149-155
35. Lorson C, Pintel DJ (1997) Characterization of the minute virus of mice P38 core promoter elements. J Virol 71:6568-6575
36. Lu Y, Sega E, Leamon CP, Low PS (2004) Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 56:1161-1176
37. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV (2006) Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24:198-204
38. Manno CS, Chew AJ, Hutchison S, et al (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972
39. Manno CS, Arruda VR, Pierce GF, et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347
40. Mar Vista Animal Medical Center (n.d.) The canine parvovirus information center. http://www. marvistavet.com/html/body-canine-parvovirus.html. Cited 9 April 2008
41. Maxfield FR, McGraw TE (2004) Endocytic recycling. Nat Rev Mol Cell Biol 5:121-132
42. McGraw TE, Greenfield L, Maxfield FR (1987) Functional expression of the human transferrin receptor cDNA in Chinese hamster ovary cells deficient in endogenous transferrin receptor. J Cell Biol 105:207-214
43. Moskalenko M, Chen L, van Roey M, et al (2000) Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 74:1761-1766
44. Muruve DA, Cotter MJ, Zaiss AK, et al (2004) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78:5966-5972
45. Muzyczka N, Berns KI (2001) Parvoviridae: the viruses and their replication. In: Knipe DM Howley PM (eds) Fields virology, 4th edn., vol. 2. Lippincott Williams and Wilkins, Philadelphia, pp 2327-2359
46. Nagayasu A, Uchiyama K, Kiwada H (1999) The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 40:75-87
47. National Cancer Institute (2007) Defining cancer. www.cancer.gov/ cancertopics/what-is-cancer, NCI, Bethesda, MD. Cited 14 April 2008
48. Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx 2:108-119
49. Ozawa K, Ayub J, Kajigaya S, et al (1988) The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 62:2884-2889
50. Parker JS, Parrish CR (2000) Cellular uptake and infection by canine parvovirus involves rapid dynamin-regulated clathrin-mediated endocytosis, followed by slower intracellular trafficking. J Virol 74:1919-1930
51. Parker JS, Murphy WJ, Wang D, et al (2001) Canine and feline parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 75:3896-3902
52. Parker SF, Felzien LK, Perkins ND, et al (1997) Distinct domains of adenovirus E1A interact with specific cellular factors to differentially modulate human immunodeficiency virus transcription. J Virol 71:2004-2012
53. Parrish CR (1995) Pathogenesis of feline panleukopenia virus and canine parvovirus. Baillieres Clin Haematol 8:57-71
54. Peden CS, Burger C, Muzyczka N, Mandel RJ (2004) Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78:6344-6359
55. Perros M, Deleu L, Vanacker JM, et al (1995) Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells. J Virol 69:5506-5515
56. Qian Z, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharm Rev 54:561-587
57. Reddy LH (2005) Drug delivery to tumours: recent strategies. J Pharm Pharmacol 57:1231-1242
58. Reddy VS, Natarajan P, Okerberg Bet al (2001) Virus Particle Explorer (VIPER), a website for virus capsid structures and their computational analyses. J Virol 75:11943-11947
59. Reed AP, Jones EV, Miller TJ (1988) Nucleotide sequence and genome organization of canine parvovirus. J Virol 62:266-276
60. Richter M, Zhang H (2005) Receptor-targeted cancer therapy. DNA Cell Biol 24:271-282
61. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds) SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007. Cited 14 April 2008
62. Rommelaere J, Cornelis JJ (1991) Antineoplastic activity of parvoviruses. J Virol Methods 33:233-251
63. Rommelaere J, Cornelis JJ (2001) Autonomous parvoviruses. In: Hernaiz Driever P, Rabkin SD (eds) Replication-competent viruses for cancer therapy, vol. 22. Kargel, Basel, pp 100-129
64. Rommelaere J, Giese N, Cziepluch C, Cornelis JJ (2005) Parvoviruses as anticancer agents. In: Sinkovics JG, Horvath JC (eds) Marcel Dekkar, New York, pp 627-675
65. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83-90
66. Ryschich E, Huszty G, Knaebel HP, et al (2004) Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 40:1418-1422
67. Sato Y, Yamauchi N, Takahashi M, et al (2000) In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J 14:2108-2118
68. Schlehofer JR, Rentrop M, Mannel DN (1992) Parvoviruses are inefficient in inducing interferon-beta, tumor necrosis factor-alpha, or interleukin-6 in mammalian cells. Med Microbiol Immunol (Berl) 181:153-164
69. Schmid SL (1997) Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu Rev Biochem 66:511-548
70. Siegl G, Bates RC, Berns KI, et al (1985) Characteristics and taxonomy of Parvoviridae. Intervirology 23:61-73
71. Singh P, Destito G, Schneemann A, Manchester M (2006) Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology 4:2
72. Spegelaere P, van Hille B, Spruyt N, et al (1991) Initiation of transcription from the minute virus of mice P4 promoter is stimulated in rat cells expressing a c-Ha-ras oncogene. J Virol 65:4919-4928
73. Spicer J, Harper P (2005) Targeted therapies for non-small cell lung cancer. Int J Clin Pract 59:1055-1062
74. Spragg DD, Alford DR, Greferath R, et al (1997) Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A 94:8795-8800
75. Suikkanen S, Saajarvi K, Hirsimaki J, et al (2002) Role of recycling endosomes and lysosomes in dynein-dependent entry of canine parvovirus. J Virol 76:4401-4411
76. Sun JY, Anand-Jawa V, Chatterjee S, Wong KK (2003) Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 10:964-976
77. Tabata Y, Murakami Y, Ikada Y (1998) Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J Control Release 50:123-133
78. Toolan HW, Saunders EL, Southam CM, et al (1965) H-1 virus viremia in the human. Proc Soc Exp Biol Med 119:711-715
79. Tsao J, Chapman MS, Agbandje M, et al (1991) The three-dimensional structure of canine parvovirus and its functional implications. Science 251:1456-1464
80. Wang Q, Kaltgrad E, Lin T, et al (2002a) Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem Biol 9:805-811
81. Wang Q, Lin T, Johnson J, Finn M (2002b) Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem Biol 9:813-819
82. Wang Q, Chan TR, Hilgraf R, et al (2003) Bioconjugation by copper(I)-catalyzed azide-alkyne [3+2] cycloaddition. J Am Chem Soc 125:3192-3193
83. WHO (2003) World cancer report. World Health Organization, Geneva
84. Young LS, Searle PF, Onion D, Mautner V (2006) Viral gene therapy strategies: from basic science to clinical application. J Pathol 208:299-318
85. Yuan W, Parrish CR (2001) Canine parvovirus capsid assembly and differences in mammalian and insect cells. Virology 279:546-557
86. Zalipsky S, Mullah N, Harding JA, et al (1997) Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug Chem 8:111-118